Legal Opinion
Corban v. Sarepta Therapeutics, Inc.
Court of Appeals for the First Circuit
Decided August 22, 2017No. 15-2135PPublishedCited by 15 opinions
1Opinion of the Court
KAYATTA, Circuit Judge.
The price of the publicly traded securities issued by Sarepta Therapeutics, Inc. dropped sixty-four percent when Sarepta announced that the Food and Drug Administration deemed premature Sarepta’s application for approval of a novel gene therapy. Promptly thereafter,. several shareholders brought this securities fraud class action against Sarepta as well as former and current Sarepta executives on behalf of those who bought Sarepta stock during the prior four months while Sarep-ta was expressing conditional optimism that the FDA would accept its application. The district…
2Cases cited24 opinions
- Tellabs, Inc. v. Makor Issues & Rights, Ltd.Supreme Court of the United States · 2007
- Ernst & Ernst v. HochfelderSupreme Court of the United States · 1976
- Zucco Partners, LLC v. Digimarc Corp.Court of Appeals for the Ninth Circuit · 2009
- Roman Zak v. Chelsea Therapeutics InternationalCourt of Appeals for the Fourth Circuit · 2015
- Greebel v. FTP Software, Inc.Court of Appeals for the First Circuit · 1999
19 more not listed; retrieve them via the Exa API.
3Cited by15 opinions
- Kader v. Sarepta Therapeutics, Inc.Court of Appeals for the First Circuit · 2018
- Yan v. ReWalk Robotics Ltd.Court of Appeals for the First Circuit · 2020
- Pike v. BuddCourt of Appeals for the First Circuit · 2025
- SEC v. LemelsonCourt of Appeals for the First Circuit · 2023
- Securities & Exchange Comm'n v. JohnstonCourt of Appeals for the First Circuit · 2021
10 more not listed; retrieve them via the Exa API.